APA (7th ed.) Citation

MR, S., J, P., Y, K., JH, S., R, P., JE, C., . . . D, S. (2026). Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(20), 1876. https://doi.org/10.1200/JCO-25-01525

Chicago Style (17th ed.) Citation

MR, Sharma, et al. "Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel C-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 44, no. 20 (2026): 1876. https://doi.org/10.1200/JCO-25-01525.

MLA (9th ed.) Citation

MR, Sharma, et al. "Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel C-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 44, no. 20, 2026, p. 1876, https://doi.org/10.1200/JCO-25-01525.